Menu
Support Programs Support Programs

AkebiaCares—YOUR PARTNER IN COVERAGE SOLUTIONS

Discover how AkebiaCares can help identify AURYXIA coverage solutions for your patients

REIMBURSEMENT HELP

One-on-one support for assistance with insurance questions and challenges

What does it offer?

  • Verify insurance and prescription drug benefits for AURYXIA
  • Coordinate prior authorizations for AURYXIA
  • Identify patient eligibility status for Low-Income Subsidy Assistance, Copay Assistance, or State‑funded programs*

Who is it for?

  • Anyone who has been prescribed AURYXIA

What form is needed?

COPAY PROGRAM

Financial assistance for patients with commercial insurance

What does it offer?

  • Up to $500 in copay savings per 30-day fill, with some patients paying as little as $0

Who is it for?

  • Eligible patients with commercial insurance

What form is needed?

  • Many pharmacies will apply the coupon when filling AURYXIA. Download the Copay Coupon

PATIENT ASSISTANCE PROGRAM (PAP)

Free AURYXIA for eligible patients who are unable to afford their copays

What does it offer?

  • Medication free of charge for eligible patients

Who is it for?

  • Uninsured patients
  • Medicare Part D patients who cannot afford copays

What form is needed?

AkebiaCares does not guarantee coverage and/or reimbursement for all patients.

*Patients may be eligible for LIS if they have an income of ≤150% of the Federal Poverty Level (FPL).

Akebia is entitled to request additional documentation for income attestation and medication drug list.

Copay assistance is not valid for prescriptions reimbursed under Medicare, Medicaid, or similar federal or state programs.

INDICATIONS

AURYXIA® (ferric citrate) is indicated for:

  • The control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis
  • The treatment of iron deficiency anemia in adult patients with chronic kidney disease not on dialysis

IMPORTANT SAFETY INFORMATION

CONTRAINDICATION

AURYXIA® (ferric citrate) is contraindicated in patients with iron overload syndromes, e.g., hemochromatosis

WARNINGS AND PRECAUTIONS

  • Iron Overload: Increases in serum ferritin and transferrin saturation (TSAT) were observed in clinical trials with AURYXIA in patients with chronic kidney disease (CKD) on dialysis treated for hyperphosphatemia, which may lead to excessive elevations in iron stores. Assess iron parameters prior to initiating AURYXIA and monitor while on therapy. Patients receiving concomitant intravenous (IV) iron may require a reduction in dose or discontinuation of IV iron therapy
  • Risk of Overdosage in Children Due to Accidental Ingestion: Accidental ingestion and resulting overdose of iron-containing products is a leading cause of fatal poisoning in children under 6 years of age. Advise patients of the risks to children and to keep AURYXIA out of the reach of children

ADVERSE REACTIONS

The most common adverse reactions reported with AURYXIA in clinical trials were:

  • Hyperphosphatemia in CKD on Dialysis: Diarrhea (21%), discolored feces (19%), nausea (11%), constipation (8%), vomiting (7%) and cough (6%)
  • Iron Deficiency Anemia in CKD Not on Dialysis: Discolored feces (22%), diarrhea (21%), constipation (18%), nausea (10%), abdominal pain (5%) and hyperkalemia (5%)

SPECIFIC POPULATIONS

  • Pregnancy and Lactation: There are no available data on AURYXIA use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. However, an overdose of iron in pregnant women may carry a risk for spontaneous abortion, gestational diabetes and fetal malformation. Data from rat studies have shown the transfer of iron into milk, hence, there is a possibility of infant exposure when AURYXIA is administered to a nursing woman

To report suspected adverse reactions, contact Akebia Therapeutics, Inc. at 1-844-445-3799

Please see full Prescribing Information